These THLs were dual conjugated with both the HIRMAb, to target the HIR on the human glial cells, and the 8D3 TfRMAb, to target the mouse TfR on the tumor vascular endothelium, which originates from mouse brain. This evidence concerns the gene TFRC and neoplasm.